HOME
SEARCH
RSS FEED
SUBSCRIBE
The Use of alpha-4 beta-7 integrin Inhibitors to Inhibit HIV Transmission and Infection
Case ID:
TAB-1708
Web Published:
12/6/2022
Description:
This invention involves the use of inhibitors of alpha-4 beta-7 (a4b7) integrin to inhibit HIV transmission/infection, as a prophylactic to inhibit onset of the acute stage of HIV infection or to treat HIV infection. The a4b7 integrin inhibitors were previously developed for use in other diseases, such as multiple sclerosis or inflammatory bowel disease.
a4b7 integrin is a multifaceted target for HIV infection and recent studies indicate that it is important for establishing HIV infection through multiple paths. Studies indicate that: 1) CD4 T-cells present in vaginal and anal mucosa have high levels of a4b7 integrin, making CD4 T-cells permissive to HIV infection; 2) a4b7 integrin is important for cell to cell transmission of HIV; 3) a4b7 integrin is used to dysregulate the host humoral response to HIV; and 4) HIV acts on a4b7 integrin through an epitope in V2 loop of GP120, identified as important for HIV vaccine protection. Additionally, primate studies indicate that a4b7 integrin inhibition of HIV infection preserves gut-associated lymphoid tissue (GALT) generally destroyed during the acute phase of HIV infection.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/The_Use_of_alpha-4_beta-7_integrin_I nhibitors_to_Inhibit_HIV_Transmission_and_Infection
Category(s):
Collaboration
Therapeutics
Infectious Disease
Bookmark this page
Download as PDF
For Information, Contact:
Chris Kornak
Lead Technology Transfer and Patent Specialist
NIH Technology Transfer
chris.kornak@nih.gov
Inventors:
Anthony Fauci
Claudia Cicala
Diana Goode
James Arthos
Keywords:
ANTAGONISTS
BBXXXX
BETWEEN
DB4AXX
DB4XXX
DBXXXX
Direct
DXXXXX
gp120
HIV
INTERACTION
Intregrin
VLXXXX
YBXXXX
YCXXXX
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum